Compare ELOG & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELOG | NXL |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | China | United States |
| Employees | N/A | 8 |
| Industry | Integrated Freight & Logistics | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 10.2M |
| IPO Year | N/A | N/A |
| Metric | ELOG | NXL |
|---|---|---|
| Price | $0.85 | $0.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.5K | ★ 223.0K |
| Earning Date | 07-17-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $15.52 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | $6.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.31 |
| 52 Week High | $3.07 | $2.00 |
| Indicator | ELOG | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 41.32 | 55.12 |
| Support Level | N/A | $0.35 |
| Resistance Level | $0.97 | $0.49 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 72.11 |
Eastern International Ltd is a holding company. The company operates through its subsidiary engaged in domestic and cross-border professional logistic services including project logistics and general logistics for company clients. Its project logistic services include Construction project logistics and special cargo logistics for large or precision equipment and General logistic services refer to the transportation, warehousing, loading and unloading, and distribution of ordinary products.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.